Redeye returns with a research update following the Q4 report and recent events in the company.
Genetic Analysis, ett medicintekniskt diagnostikbolag inriktat mot mikrobiota, har under 2022 etable...
Scandion’s Q422 and FY22 results highlighted the significance of the upcoming year, with key clinica...
Obducat fortsätter att vinna fler affärer där orderstocken vid utgången av december 2022 uppgick til...
FY22 was marked by several clinical milestones for Mendus, notably the positive survival data from t...
Redeye comments on Azelio’s year-end report, which puts future financing in the spotlight.
Rekordomsättning för båda segmenten avslutar året Omsättningen under det fjärde kvartalet uppgick ti...
Rapportkommentar Calliditas släppte under torsdagen en rapport som slog våra försäljningsestimat, me...
Stark Q4 rapport med återhämtning från Q3’22 Sensys Gatso rapporterade en stark Q4.
Avslutar året rekordstarkt CAG avslutar året med ett rekordkvartal som överträffar våra förväntninga...
Veg of Lunds nettoomsättning uppgick till 2,5 (2,6) miljoner kronor under 2022.
Redeye provides its initial thoughts on Heliospectra’s fourth-quarter report, which showed net sales...
Dovre disclosed Q4 figures before the report and thus there were no big surprises.
Redeye notes that Alzecure’s Q4 report presented revenues of SEK0m and net result of SEK-11m, which ...
Q4'22 pre-tax profit in line with ABGSC Just soft on NII but strong in the subsegments Delivering th...
North America recovered in Q4 as expected, grew 17% org.
Redeye comments on Imint’s Q4 2022 report, which came in weaker than expected, both in terms of sale...
Q4 EBITA SEK 58m (+9% vs. ABGSCe) Organic growth was 21% vs.
Redeye comments on Embracers Groups multi-year agreement with New Line Cinema and Warner Bros regard...
